Applied Therapeutics, Inc. (NASDAQ:APLT - Get Free Report) traded down 2.2% during trading on Wednesday . The stock traded as low as $8.94 and last traded at $8.94. 144,711 shares traded hands during trading, a decline of 92% from the average session volume of 1,845,457 shares. The stock had previously closed at $9.14.
Wall Street Analysts Forecast Growth
APLT has been the subject of several analyst reports. Leerink Partners increased their price target on Applied Therapeutics from $11.00 to $14.00 and gave the stock an "outperform" rating in a research report on Thursday, September 19th. William Blair upgraded Applied Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. Royal Bank of Canada reissued an "outperform" rating and set a $12.00 target price on shares of Applied Therapeutics in a report on Wednesday, July 17th. Finally, Citigroup lifted their price target on Applied Therapeutics from $8.00 to $11.00 and gave the stock a "buy" rating in a research note on Thursday, September 19th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Applied Therapeutics presently has an average rating of "Buy" and a consensus target price of $12.50.
Read Our Latest Stock Analysis on APLT
Applied Therapeutics Stock Down 3.8 %
The stock has a 50-day moving average price of $6.75 and a 200 day moving average price of $5.53. The firm has a market capitalization of $1.00 billion, a price-to-earnings ratio of -4.78 and a beta of 2.04.
Applied Therapeutics (NASDAQ:APLT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.03). The firm had revenue of $0.14 million for the quarter, compared to analyst estimates of $10.00 million. As a group, equities analysts forecast that Applied Therapeutics, Inc. will post -0.48 earnings per share for the current fiscal year.
Insider Buying and Selling at Applied Therapeutics
In other Applied Therapeutics news, CEO Shoshana Shendelman sold 300,000 shares of the business's stock in a transaction on Monday, August 12th. The shares were sold at an average price of $5.98, for a total value of $1,794,000.00. Following the transaction, the chief executive officer now directly owns 5,167,853 shares of the company's stock, valued at approximately $30,903,760.94. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.60% of the stock is owned by company insiders.
Institutional Investors Weigh In On Applied Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. acquired a new position in shares of Applied Therapeutics in the second quarter valued at approximately $54,000. Principal Financial Group Inc. acquired a new stake in shares of Applied Therapeutics in the second quarter worth approximately $54,000. SG Americas Securities LLC purchased a new stake in Applied Therapeutics in the second quarter valued at approximately $87,000. Algert Global LLC purchased a new stake in Applied Therapeutics in the second quarter valued at approximately $110,000. Finally, Denali Advisors LLC acquired a new position in Applied Therapeutics during the first quarter worth approximately $228,000. 98.31% of the stock is currently owned by institutional investors and hedge funds.
About Applied Therapeutics
(
Get Free Report)
Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.
See Also
Before you consider Applied Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Applied Therapeutics wasn't on the list.
While Applied Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
